Literature DB >> 15136242

Prostatic acid phosphatase: a possible diagnostic marker of intravascular large B-cell lymphoma.

Yukiko Kishi1, Masahiro Kami, Eiji Kusumi, Tomoka Mineyama, Daisuke Kato, Tamae Hamaki, Jun-ichi Ueyama, Shigesaburo Miyakoshi, Shin-ichi Morinaga, Yoshitomo Muto, Shuichi Taniguchi.   

Abstract

BACKGROUND AND
OBJECTIVE: Intravascular large B-cell lymphoma (IVL) has been treated as fever of unknown origin (FUO), and many patients have been treated inadequately based on incorrect diagnoses. We previously cares for a patient with IVL who tested positive for prostatic acid phosphatase (PAP), a marker of prostate cancer. Since then, we have regularly examined this mather when IVL was suspected to investigate the usefulness of PAP as a diagnostic marker for IVL. We retrospectively evaluated the usefulness of PAP as diagnostic marker of IVL. DESIGN AND METHODS: We reviewed the clinical courses of 5 patients with IVL (3 males, 2 females) in comparison with 23 controls with hematologic malignancies other than IVL.
RESULTS: Serum levels of PAP were elevated in all 5 patients with IVL and 2 of the 23 controls. The difference was statistically significant using a chi-squared test (p=0.0002). The sensitivity and specificity of PAP were 100% and 91%, respectively, in the diagnosis of IVL. Its serum levels were closely associated with disease status. INTERPRETATION AND
CONCLUSIONS: This study suggests that PAP might be a useful marker for the screening and assessment of disease activity and responses to the treatment of IVL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136242

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  1 in total

1.  Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.

Authors:  Judit Csomor; Ilona Kaszás; Balázs Kollár; László Pajor; Zsolt Egyházi; Sándor Fekete; Miklós Egyed; Botond Timár
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.